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Bayesian regression models, which are more ﬂexible and are
simple to implement in freely available software. RESULTS:
Using health outcomes research examples for illustration in each
case, we describe common methodology issues arising from use
of these methods, such as when small numbers of trials are
analysed, when unequal trial sizes are included and when excess
variability between trials (or heterogeneity) is encountered.
CONCLUSIONS: For the methods considered, we offer possible
solutions, make recommendations for their use and point out sit-
uations in which caution should be exercised.
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EVALUATING THE DIFFERENCE BETWEEN AVERAGE
WHOLESALE PRICE AND WHOLESALE ACQUISITION COST
FOR PHARMACEUTICALS IN THE UNITED STATES
Malone DC, Mahmood M
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OBJECTIVES: 1) To examine the percent difference between
average wholesale price (AWP) and wholesale acquisition cost
(WAC) for pharmaceuticals in the United States, accounting 
for patent status and manufacturer type, and 2) to evaluate the
relationship between brand manufacturers and relabelers.
METHODS: Data for this study came from the Master Drug
Data Base (MDDB), which is a proprietary drug ﬁle containing
pricing information for all prescription and non-prescription
products available in the US. The percent difference between
AWP and WAC for prescription pharmaceuticals was compared
on a variety of facets, including single source, type of manufac-
turer (original or repackager). The difference was expressed as a
percentage of AWP (a commonly used method for reimbursing
pharmacies in the US). We also compared the AWP among brand
name manufacturers and relabelers (who repackage brand name
pharmaceuticals produced by the original manufacturer).
RESULTS: A total of 23,607 unique drug products were included
in the analysis examining AWP and WAC. The mean percent dif-
ference for brand name pharmaceuticals was 0.23 + 0.11, as
compared to 0.44 + 0.26, p < 0.001. Brand name drugs that were
available from multiple companies had a mean difference of 0.25
+ 0.14, compared to 0.20 + 0.05 for single source products (p <
0.001). The median AWP for brand name manufacturers was
$3.04 per unit, compared to $3.11 per unit for relablers. CON-
CLUSION: This study documents the magnitude of well-known
differences between AWP and WAC for brand name and generic
products. Further, branded products produced by more than one
manufacturer will have larger differences between AWP and
WAC than single source products. The ﬁndings suggest the need
for analysts to critically evaluate the use of AWP for determin-
ing product costs in the US and substantial differences exist
between single source and multiple source products. A more
transparent and accurate pricing system is needed for economic
analyses in the US.
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RELATIVE WEIGHTS ASSIGNED TO PHARMACY
PROCEDURES: OPPS METHODS DESIGN AND CONCEPTS
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OBJECTIVE: The Centers for Medicare and Medicaid Services
(CMS) assigns relative weights to procedures in the hospital out-
patient setting and may do so for pharmacy handling costs in
2006. This study examines the current approach to assignment
of relative weights for drug and biological administration codes
under the CMS Hospital Outpatient Prospective Payment System
(OPPS) and compares this approach to the resource-based level
of effort concept initially created for payment to physicians.
METHODS: Resource-based methods originally proposed for
the hospital OPPS and equivalent measurement methods in the
original Harvard RBRVS work were deconstructed and evalu-
ated. The MedPAC rationale for recommendation of relative
weights for payment of pharmacy handling costs and the pro-
posed weights were also examined and evaluated. RESULTS:
The evaluation sought indications of resource-based level of
effort applications in the OPPS and their comparability to the
original resource-based studies, especially in the area of intensity
measures. The underlying intent of the resource-based relative
value scale (RBRVS) was to create a hierarchy of resource-based
level of effort in physician service delivery. The concept of hos-
pital OPPS was also intended to reﬂect resource-based service
delivery. Procedures are assigned a relative weight, implying that
payment includes level of effort resources. Recommended 2006
handling costs for drugs are assigned ﬁve relative weights, each
compared to drawing up an injected drug for administration. We
postulate these relative weights contain insufﬁcient recognition
of the level of effort and resource consumption required, thus
distorting the concept’s initial intent. CONCLUSIONS: Many
researchers and policy makers assume that relative weights
equate to level of effort resource consumption in all instances.
We cannot ﬁnd this is so regarding the ﬁve levels of relative
weights recommended for OPPS pharmacy handling costs.
Because resource consumption is disproportionately greater than
relative weights assigned in many cases, the resulting payment
will be understated.
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OBJECTIVES: Pharmacoeconomic evaluation activities have
grown rapidly in recent years, but few economic evaluations
have focused on Medical Devices (MD). This study addresses the
barriers to conducting economic evaluations of MD, in compar-
ison with pharmacoeconomic evaluations, in order to develop a
framework for MD economic evaluation. METHODS: First, we
studied the differences between MD and drugs that possibly
impact on the completion of economic evaluations. Then, we
analysed items of the French Guidelines for Economic Evalua-
tions of Health Care Technologies developed by the “Collège des
Economistes de la Santé” [http://www.ces-asso.org/docs/France_
Guidelines_HE_Evaluation.PDF] that might be barriers to the
completion of MD economic evaluations, as compared to drugs,
and we developed suggestions to overcome these barriers.
RESULTS: In this abstract we present three of eight barriers to
performing economic evaluations of MD. The ﬁrst one relates to
the feasibility of clinical trials, e.g. inadequacy of “placebo” and
“double blinding” for MD testing and difﬁculty to include large
numbers of patients. We suggest performing comparative studies
for assessing clinical outcomes to be included in economic eval-
uations and to discuss potential bias. Secondly, MD is developed
by engineers who are used to assessing technical performance,
but not clinical and economic outcomes. We propose setting up
collaborations between engineers, health care professionals and
health economists from the very beginning of MD development.
Besides, MD effectiveness often depends on the operator (health
care professional or patient) and may change over time, when
the operator gains experience. Health economists must, there-
fore, analyse the transferability of economic evaluation results
from one setting to another and over time. CONCLUSION: We
recommend setting up multidisciplinary groups of engineers,
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health care professionals and health economists from the begin-
ning of MD development; and deﬁning MD to be evaluated in
priority, on which economic evaluation methods should be tested
before being applied to others.
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(PE/HE) IN LOCAL HEALTH CARE DECISION MAKING (DM)
Soto H1, Guzman S2, Reynoso N2, Cortes L3
1Universidad Autonoma del Estado de Mexico,Toluca, Mexico;
2Universidad Autonoma del Estado de Mexico, Estado de México,
Mexico; 3Instituto Mexicano de Seguro Social, Guadalajara, Mexico
OBJCETIVE: To evaluate the basic knowledge level of DM
(General manager of the Hospital-GMH- and Chief of clinical
service-SCS-) about the application of PE/HE tool as inﬂuence
characteristics in decision make as well as main advantages and
obstacles. METHODS: A transversal survey was performing. In
a not related forum, DM was invited to complete a self-report
questionnaire about utilization of concepts of PE/HE in local
health care decision make. The main inclusion criteria were the
DM taken part in the process of evaluation inclusions of drugs
on the basic formulary. Descriptive and multivariate analysis test
were applied. RESULTS: A total of 139 questionnaires were
included for the analysis. Male 76.98%, the mean of (SD): age
48.28 (+6.35), time of labour experience 19.5 (+7.02). The
30.22% was SCS and 14.39% were GMH. The more important
characteristics for inclusions of drugs on the basic formulary are
efﬁcacy (82.73%) and safety and tolerability (76.94%). The
PE/HE was ﬁfth (64.03%). 44.60% had training in PE/HE
topics. Cost-beneﬁt was the concept mentioned more frequently
(75.54%). The 68.35% used PE/HE for inclusions of drugs on
the basic formulary. The probability of using PE/HE is 3.97 times
stolen high if DM has taken PE/HE course. The perception of
the group of the advantages de PE/HE help them to optimize the
resource (54.68%) and to give validation and realiable informa-
tion (7.91%). About the obstacle of use of PE/HE, DM men-
tioned the difﬁcult of access of the PE/HE (36.20%) and lack of
training (20.69%). A low percentage of participate wrote correct
the concepts of PE/HE. CONCLUSIONS: It is important to
strengthen the knowledge and utilization of the PE/HE tools in
Mexican DM.
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Fitzgerald P,Tilden D,Aristides M
M-TAG, A division of IMS Health Economics and Outcomes
Research, London, UK
OBJECTIVES: Utilities are increasingly used to measure quality
of life (QoL) for health states, and a variety of instruments can
be used for this purpose. When QOL measures for different
groups are obtained using different instruments, comparing
summary statistics formally is difﬁcult and there is nothing
described in the methodology or applied literature. In this pre-
sentation we propose a relatively simple approach for compar-
ing QoL mean scores from EuroQoL and AqoL questionnaires
indirectly when this situation is encountered, which leads to a
result equivalent to that of a t-test. METHODS: Using an
example from a utility study for illustration, we describe a
method based on multiple imputation (MI), an approach com-
monly used to deal with missing data. From an estimate of the
correlation between the total mean scores, we describe how
simple linear regression can be used to obtain imputed values of
EuroQoL scores from AQoL scores. The multiple imputation
approach then offers simple techniques to obtain pooled esti-
mates of mean difference and variance on the EuroQoL scale.
RESULTS: We show how the resulting data can be used in a
simple way to generate a valid t-test statistic on the same QoL
scale. We then brieﬂy discuss the strengths and weaknesses of
this approach from the point of view of QoL measures as well
as methodology. CONCLUSIONS: The approach we present can
be used to compare data from different QoL instruments. We
summarise the circumstances under which such comparisons
would be valid, and also highlight situations when this approach
should not be used.
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OBJECTIVES: To describe the development and validation of a
Dutch version of the London Handicap Scale (DLHS). This ques-
tionnaire was based on the London Handicap Scale, a valid and
reliable utility instrument for measuring social participation in
adults. METHODS: The DLHS was tested in 803 adults with a
questionnaire consisting of the DLHS itself, the Impact on Par-
ticipation and Autonomy’ questionnaire (IPA), the Dutch version
of the EuroQol EQ-5D and questions concerning e.g. chronic
diseases, use of medical devices. The study population consisted
of patients with rheumatoid arthritis, cara/asthma, epilepsy,
larynchetomy and multiple sclerosis. RESULTS: Content valida-
tion, evaluated by relating the scores on the dimensions of the
DLHS and the number of chronic diseases was satisfactory. Con-
ceptual validation was shown by large (or some moderate,
almost large) correlations of predeﬁned pairs of the DLHS
dimensions with domains of the IPA. Correlations between the
DLHS sumscore and the IPA subscales were considerably larger
than corresponding correlations between the EQ-5D and the IPA
subscales, indicating a good concurrent validity of the DLHS.
The ability of the DLHS to discriminate between various sub-
groups of chronically ill persons ﬁve criteria was shown by cor-
relating the DLHS sumscore with ﬁve predeﬁned criteria.
CONCLUSIONS: Based on this evaluation the questionnaire
seems feasible and valid for assessing differences between differ-
ent subgroups of chronically ill or disabled persons in The
Netherlands.
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OBJECTIVES: Desferal (DFO), the most common CT for IO,
requires infusions of 8–12 hours, 5–7 days per week. Oral for-
mulations are in development. Consequences of the high burden
of current chelation therapy with Desferal are poor treatment
adherence and satisfaction potentially leading to sub-optimal
clinical outcome. However, CT-speciﬁc satisfaction question-
naires have not been developed. METHODS: Five steps were
taken to develop the satisfaction questionnaire: literature review,
patient interviews, clinician interviews, item generation and
content validity testing. Three IO expert interviews and four
patient interview transcripts were reviewed to assess satisfaction
with DFO and reactions to a hypothetical oral CT. Items were
developed based on these steps and tested in nine patients
